Skip to main content

Table 3 Baseline characteristics

From: Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis

Trial Aetiology of respiratory failurea Treatment group Age (years) Initial PaO2/FiO2 PRISM score
Luchetti, 1998 Bronchiolitis Pneumonia 100% Surfactant 0.87 (0.15) 118 (15.8) Not reported
   50% Placebo 0.93 (0.17) 122 (12.0) Not reported
Willson, 1999 ARDS 31%     
  Pneumonia 26% Surfactant 5.0 (5.34) 102 (53) 12 (6)
  RSV 17% Placebo 4.5 (5.66) 105 (42) 9 (4)
  Near-drowning 7%     
  Sepsis 7%     
  Other 14%     
Tibby, 2000 RSV 100% Surfactant 0.17 (0.14, 0.27)b 146 (134, 171)b 11 (11, 15)b
    Placebo 0.13 (0.09, 0.18)b 160 (106, 205)b 13 (11, 15)b
Luchetti, 2002 RSV 100% Surfactant 0.73 (0.675) Not reported 12 (1.1)
  Pneumonia 45% Placebo 0.62 (0.542) Not reported 12 (1.2)
Moller, 2003 Pneumonia 68% Surfactant 3.5 (range 0–13) 71 (13.7) 12 (6.5)
  Sepsis 32% Placebo 4.5 (range (0–12) 64 (16.2) 11 (4.5)
Willson, 2005 ARDS or sepsis 35% Surfactant 7.2 (6.4) 128 (54) 15 (9.4)
  Pneumonia 42% Placebo 6.7 (6.4) 126 (73) 14 (7.9)
  RSV 7%     
  Near-drowning 5%     
  Other 11%     
  1. Values expressed as the mean (standard deviation) unless otherwise indicated. ARDS: acute respiratory distress syndrome; PRISM, Pediatric Risk of Mortality; RSV: respiratory syncytial virus. aTotals may be greater than 100% due to rounding and because multiple aetiologies were reported for some patients. bMedian (interquartile range).